Pfizer: 3 Key Takeaways for Long-Term Investors
The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.